vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and Donnelley Financial Solutions, Inc. (DFIN). Click either name above to swap in a different company.
ANI PHARMACEUTICALS INC is the larger business by last-quarter revenue ($247.1M vs $172.5M, roughly 1.4× Donnelley Financial Solutions, Inc.). ANI PHARMACEUTICALS INC runs the higher net margin — 11.1% vs 3.6%, a 7.5% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs 10.4%). Donnelley Financial Solutions, Inc. produced more free cash flow last quarter ($47.9M vs $29.1M). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs -7.9%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
Donnelley Financial Solutions (DFIN) is a financial compliance company based in Chicago, Illinois, United States. The company provides software as a service (SaaS) products, software-enabled services (SeS), print, and compliance services related to US Securities and Exchange Commission regulations to companies in capital and investment markets.
ANIP vs DFIN — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $172.5M |
| Net Profit | $27.5M | $6.2M |
| Gross Margin | — | — |
| Operating Margin | 14.1% | 8.3% |
| Net Margin | 11.1% | 3.6% |
| Revenue YoY | 29.6% | 10.4% |
| Net Profit YoY | 367.5% | -1.6% |
| EPS (diluted) | $1.14 | $0.31 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | $172.5M | ||
| Q3 25 | $227.8M | $175.3M | ||
| Q2 25 | $211.4M | $218.1M | ||
| Q1 25 | $197.1M | $201.1M | ||
| Q4 24 | $190.6M | $156.3M | ||
| Q3 24 | $148.3M | $179.5M | ||
| Q2 24 | $138.0M | $242.7M | ||
| Q1 24 | $137.4M | $203.4M |
| Q4 25 | $27.5M | $6.2M | ||
| Q3 25 | $26.6M | $-40.9M | ||
| Q2 25 | $8.5M | $36.1M | ||
| Q1 25 | $15.7M | $31.0M | ||
| Q4 24 | $-10.3M | $6.3M | ||
| Q3 24 | $-24.2M | $8.7M | ||
| Q2 24 | $-2.3M | $44.1M | ||
| Q1 24 | $18.2M | $33.3M |
| Q4 25 | 14.1% | 8.3% | ||
| Q3 25 | 15.9% | 16.1% | ||
| Q2 25 | 6.6% | 24.2% | ||
| Q1 25 | 13.3% | 22.8% | ||
| Q4 24 | -2.3% | 6.0% | ||
| Q3 24 | -13.8% | 10.1% | ||
| Q2 24 | 3.7% | 26.6% | ||
| Q1 24 | 14.8% | 21.9% |
| Q4 25 | 11.1% | 3.6% | ||
| Q3 25 | 11.7% | -23.3% | ||
| Q2 25 | 4.0% | 16.6% | ||
| Q1 25 | 8.0% | 15.4% | ||
| Q4 24 | -5.4% | 4.0% | ||
| Q3 24 | -16.3% | 4.8% | ||
| Q2 24 | -1.7% | 18.2% | ||
| Q1 24 | 13.2% | 16.4% |
| Q4 25 | $1.14 | $0.31 | ||
| Q3 25 | $1.13 | $-1.49 | ||
| Q2 25 | $0.36 | $1.28 | ||
| Q1 25 | $0.69 | $1.05 | ||
| Q4 24 | $-0.45 | $0.21 | ||
| Q3 24 | $-1.27 | $0.29 | ||
| Q2 24 | $-0.14 | $1.47 | ||
| Q1 24 | $0.82 | $1.09 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $24.5M |
| Total DebtLower is stronger | — | $171.3M |
| Stockholders' EquityBook value | $540.7M | $379.2M |
| Total Assets | $1.4B | $800.4M |
| Debt / EquityLower = less leverage | — | 0.45× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | $24.5M | ||
| Q3 25 | $262.6M | $22.7M | ||
| Q2 25 | $217.8M | $33.8M | ||
| Q1 25 | $149.8M | $16.2M | ||
| Q4 24 | $144.9M | $57.3M | ||
| Q3 24 | $145.0M | $33.6M | ||
| Q2 24 | $240.1M | $35.0M | ||
| Q1 24 | $228.6M | $43.7M |
| Q4 25 | — | $171.3M | ||
| Q3 25 | — | $154.7M | ||
| Q2 25 | — | $190.1M | ||
| Q1 25 | — | $189.5M | ||
| Q4 24 | — | $124.7M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $540.7M | $379.2M | ||
| Q3 25 | $505.8M | $423.1M | ||
| Q2 25 | $436.8M | $432.1M | ||
| Q1 25 | $418.6M | $419.9M | ||
| Q4 24 | $403.7M | $436.1M | ||
| Q3 24 | $405.9M | $444.5M | ||
| Q2 24 | $455.8M | $441.5M | ||
| Q1 24 | $452.0M | $408.9M |
| Q4 25 | $1.4B | $800.4M | ||
| Q3 25 | $1.4B | $816.3M | ||
| Q2 25 | $1.3B | $874.7M | ||
| Q1 25 | $1.3B | $852.8M | ||
| Q4 24 | $1.3B | $841.6M | ||
| Q3 24 | $1.3B | $843.6M | ||
| Q2 24 | $920.8M | $882.9M | ||
| Q1 24 | $914.5M | $867.8M |
| Q4 25 | — | 0.45× | ||
| Q3 25 | — | 0.37× | ||
| Q2 25 | — | 0.44× | ||
| Q1 25 | — | 0.45× | ||
| Q4 24 | — | 0.29× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $59.8M |
| Free Cash FlowOCF − Capex | $29.1M | $47.9M |
| FCF MarginFCF / Revenue | 11.8% | 27.8% |
| Capex IntensityCapex / Revenue | 0.5% | 6.9% |
| Cash ConversionOCF / Net Profit | 1.10× | 9.65× |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $107.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $59.8M | ||
| Q3 25 | $44.1M | $74.4M | ||
| Q2 25 | $75.8M | $68.4M | ||
| Q1 25 | $35.0M | $-37.7M | ||
| Q4 24 | $15.9M | $56.4M | ||
| Q3 24 | $12.5M | $86.4M | ||
| Q2 24 | $17.4M | $56.2M | ||
| Q1 24 | $18.3M | $-27.9M |
| Q4 25 | $29.1M | $47.9M | ||
| Q3 25 | $38.0M | $59.2M | ||
| Q2 25 | $71.8M | $51.7M | ||
| Q1 25 | $32.5M | $-51.0M | ||
| Q4 24 | $13.5M | $41.3M | ||
| Q3 24 | $7.7M | $67.3M | ||
| Q2 24 | $13.0M | $36.8M | ||
| Q1 24 | $13.7M | $-40.2M |
| Q4 25 | 11.8% | 27.8% | ||
| Q3 25 | 16.7% | 33.8% | ||
| Q2 25 | 34.0% | 23.7% | ||
| Q1 25 | 16.5% | -25.4% | ||
| Q4 24 | 7.1% | 26.4% | ||
| Q3 24 | 5.2% | 37.5% | ||
| Q2 24 | 9.4% | 15.2% | ||
| Q1 24 | 10.0% | -19.8% |
| Q4 25 | 0.5% | 6.9% | ||
| Q3 25 | 2.7% | 8.7% | ||
| Q2 25 | 1.9% | 7.7% | ||
| Q1 25 | 1.3% | 6.6% | ||
| Q4 24 | 1.3% | 9.7% | ||
| Q3 24 | 3.2% | 10.6% | ||
| Q2 24 | 3.2% | 8.0% | ||
| Q1 24 | 3.3% | 6.0% |
| Q4 25 | 1.10× | 9.65× | ||
| Q3 25 | 1.66× | — | ||
| Q2 25 | 8.87× | 1.89× | ||
| Q1 25 | 2.23× | -1.22× | ||
| Q4 24 | — | 8.95× | ||
| Q3 24 | — | 9.93× | ||
| Q2 24 | — | 1.27× | ||
| Q1 24 | 1.00× | -0.84× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
DFIN
| Technology Service | $68.0M | 39% |
| Capital Markets Compliance And Communications Management | $61.6M | 36% |
| Investment Companies Software Solutions | $30.9M | 18% |
| Print And Distribution Service | $13.6M | 8% |
